OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Manufacturers face the challenge of meeting growing demand for personalized biopharmaceuticals.
Despite many development challenges, stable producer cell lines show real promise.
CPC presents a green alternative to chromatography that supports sustainable operations.
Experts outline the benefits of single-use consumables relative to traditional approaches.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
September 15, 2023
Cold chain stakeholders continue to innovate with new technology development, the use of advanced modeling and analytics capabilities, and the pursuit of strategic partnerships.
Apollo is a part of a research and development platform for the development of new medicines, with program selection being hesitant to indication and primarily driven by quality of science or the potential to transform the standard of care in major commercial markets, according to the press release.
Despite its success, clinical and logistical roadblocks to mRNA cancer vaccine development remain.
September 14, 2023
The companies are collaborating to apply ShapeTX’s AAVid capsid discovery platform and transgene engineering technology in addition to Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for eye diseases.
September 13, 2023
Recipharm will provide analytical and process development capabilities to support toxicology studies, in addition to GLP manufacturing of lipid nanoparticles to capture the active pharmaceutical ingredient, an antigen peptide.
Rentschler Biopharma’s ATMP business can now offer its full range of services for the clinical supply of AAV, including bioprocess and analytical development through to cGMP manufacturing at the Stevenage facility in the UK.
Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges.
Seagen will be responsible for conjugating these degraders to antibodies to make DACs and advancing these DAC drug candidates through preclinical and clinical development and commercialization.
September 12, 2023
The results showed that PathoQuest’s proprietary NGS approach is an effective, more robust replacement to in vivo adventitious virus testing of cell substrates used in the production of biologics, like monoclonal antibodies, vaccines, cell, and gene therapies.
September 11, 2023
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.
September 08, 2023
The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.
September 07, 2023
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.